Thomas John Dietz, Director at Eiger BioPharmaceuticals, Inc. (EIGR), bought 50,000 shares at $1.43 ($72K) on 2023-01-23, disclosed to the SEC on 2023-01-25.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| EIGR | BUY | 2021-04-12 | $21K | — | Filing → |
| EIGR | BUY | 2020-03-17 | $5K | — | Filing → |
| EIGR | BUY | 2020-01-13 | $56K | — | Filing → |